84558-93-0Relevant academic research and scientific papers
Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
-
, (2008/06/13)
Use of a compound of the formula STR1 wherein A is β-2''-deoxy-D-ribofuranosyl or β-D-arabinofuranosyl;R 1 is hydroxy or amino;R 2 is cycloalkyl or alkyl-substituted cycloalkyl containing 1-5 carbon atoms; saturated or unsaturated, straight or branched al
Process for the preparation of pyrimidine nucleosides
-
, (2008/06/13)
A process is provided for the preparation of a compound of formula (I) or a salt thereof: wherein R1 is hydrogen or a C1 4 alkyl, comprising reacting a compound of formula II: with an agent serving to introduce the alkynyl radical of formula -C≡CR1 (wherein R1 is as described above) at the 5-position of the pyrimidine base, the reaction being carried out in the presence of an N1 6 alkylmorpholine, wherein said alkyl moiety being optionally substituted by an alkoxy or halogen group; and optionally thereafter converting into a salt.
1-(β-D-arabinofuranosyl)-5-propynyluracil for treatment of VZV infections
-
, (2008/06/13)
The invention is a method for using 1-(β-D-arabinofuranosyl)-5-propynyluracil or its salts as the active ingredient in pharmaceutical compositions in the treatment of varicella zoster viral infections whether expressed as chicken pox or shingles.
Anti-HBV pyrimidine nucleoside
-
, (2008/06/13)
This invention relates to 1-(β-D-Arabinofuranosyl)5-prop-1-ynyluracil and pharmaceutically acceptable derivatives thereof for use in the treatment of hepatitis viral infections, particularly hepatitis B viral infections.
